News Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-07 am EDT			5-day change	1st Jan Change
360 ^JPY	-3.49%		-9.77%	-22.75%

12:56pm	Profit-Taking, China Outlooks Churn Asian Stock Markets	MT
May. 02	Fed Outlook, Earnings Season Roil Asian Stock Markets	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Profit-Taking, China Outlooks Churn Asian Stock Markets	06:56am	MT
Sumitomo Pharma : Posted Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024	01:55am	PU
Sumitomo Pharma : May 01, 2024 Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024 transcript	01:55am	PU
Fed Outlook, Earnings Season Roil Asian Stock Markets	May. 02	MT
Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024	May. 02	MT
Sumitomo Pharma Expects Substantial Valuation Loss on Subsidiary Shares; Assures No Impact on Consolidated Profit	May. 02	MT
Sumitomo Pharma : May 01, 2024 Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024	May. 02	PU
Sumitomo Pharma : Presentation Material (Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024)	Apr. 29	PU
Lull in Geopolitical Tensions Lifts Asian Stock Markets	Apr. 22	MT
Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold	Apr. 17	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	Mar. 17	MT
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from S&P Japan 500	Mar. 17	CI
Sumitomo Pharma : Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	Mar. 15	PU
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	Mar. 15	CI
Sumitomo Pharma Announces Availability of ORGOVYX in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer	Mar. 13	AQ
US Inflation Report Lifts Asian Stock Markets	Mar. 01	MT
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	Feb. 16	MT
Japan's Nikkei slips after Fed chair signals delay in rate cut	Jan. 31	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Summary

Filters